{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T13:15:23Z","timestamp":1778159723277,"version":"3.51.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Instituto de Salud Carlos III, University of Seville, Jerome Lejeune Foundation"},{"name":"Instituto de Salud Carlos III, University of Seville"},{"name":"Salud Carlos III, Jerome Lejeune Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10875-025-01957-0","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T07:12:25Z","timestamp":1764054745000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical and Immunological Impact of JAK Inhibition in Concurrent Down Syndrome and STAT1 Gain of Function"],"prefix":"10.1007","volume":"45","author":[{"given":"Pilar","family":"Blanco-Lobo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Gilabert-Prieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"de Felipe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Moreno-Fuentes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paloma","family":"Guisado Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Ortiz-Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Mensa-Vilar\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan I.","family":"Ar\u00f3stegui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Palmou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valle","family":"Velasco Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngela","family":"Dey\u00e0 Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Ramakers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Ivorra-Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Roca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Cordero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inmaculada","family":"Guillen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicol\u00e1s","family":"Valerdiz Men\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Manuel","family":"Lucena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirella","family":"Gaboli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Olbrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olaf","family":"Neth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"issue":"24","key":"1957_CR1","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1056\/NEJMra1706537","volume":"382","author":"MJ Bull","year":"2020","unstructured":"Bull MJ. Down syndrome. N Engl J Med. 2020;382(24):2344\u201352.","journal-title":"N Engl J Med"},{"issue":"5","key":"1957_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/jar.12446","volume":"31","author":"L O\u2019Leary","year":"2018","unstructured":"O\u2019Leary L, Hughes-McCormack L, Dunn K, Cooper SA. Early death and causes of death of people with down syndrome: a systematic review. J Appl Res Intellect Disabil. 2018;31(5):687\u2013708.","journal-title":"J Appl Res Intellect Disabil"},{"issue":"2","key":"1957_CR3","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3390\/genes12020268","volume":"12","author":"M Ferrari","year":"2021","unstructured":"Ferrari M, Stagi S. Autoimmunity and genetic syndromes: a focus on Down syndrome. Genes. 2021. https:\/\/doi.org\/10.3390\/genes12020268","journal-title":"Genes"},{"issue":"1","key":"1957_CR4","first-page":"64","volume":"9","author":"V Fitzpatrick","year":"2022","unstructured":"Fitzpatrick V, Rivelli A, Chaudhari S, Chicoine L, Jia G, Rzhetsky A, et al. Prevalence of infectious diseases among 6078 individuals with Down syndrome in the United States. J Patient-Cent Res Rev. 2022;9(1):64\u20139.","journal-title":"J Patient-Cent Res Rev"},{"issue":"4","key":"1957_CR5","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1046\/j.1440-1754.1999.00386.x","volume":"35","author":"JM Hilton","year":"1999","unstructured":"Hilton JM, Fitzgerald DA, Cooper DM. Respiratory morbidity of hospitalized children with trisomy 21. J Paediatr Child Health. 1999;35(4):383\u20136.","journal-title":"J Paediatr Child Health"},{"key":"1957_CR6","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.coi.2021.06.006","volume":"72","author":"L Malle","year":"2021","unstructured":"Malle L, Bogunovic D. Down syndrome and type I interferon: not so simple. Curr Opin Immunol. 2021;72:196\u2013205.","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"1957_CR7","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/imr.13296","volume":"322","author":"M Ramba","year":"2023","unstructured":"Ramba M, Bogunovic D. The immune system in Down syndrome: autoimmunity and severe infections. Immunol Rev. 2023. https:\/\/doi.org\/10.1111\/imr.13296","journal-title":"Immunol Rev"},{"issue":"6","key":"1957_CR8","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s10875-020-00803-9","volume":"40","author":"XF Kong","year":"2020","unstructured":"Kong XF, Worley L, Rinchai D, Bondet V, Jithesh PV, Goulet M, et al. Three copies of four interferon receptor genes underlie a mild type I interferonopathy in down syndrome. J Clin Immunol. 2020;40(6):807\u201319.","journal-title":"J Clin Immunol"},{"key":"1957_CR9","doi-asserted-by":"publisher","unstructured":"Sullivan KD, Lewis HC, Hill AA, Pandey A, Jackson LP, Cabral JM, et al. Trisomy 21 consistently activates the interferon response. Elife. 2016. https:\/\/doi.org\/10.7554\/eLife.16220","DOI":"10.7554\/eLife.16220"},{"issue":"48","key":"1957_CR10","doi-asserted-by":"publisher","first-page":"24231","DOI":"10.1073\/pnas.1908129116","volume":"116","author":"P Araya","year":"2019","unstructured":"Araya P, Waugh KA, Sullivan KD, Nunez NG, Roselli E, Smith KP, et al. Trisomy 21 dysregulates T cell lineages toward an autoimmunity-prone state associated with interferon hyperactivity. Proc Natl Acad Sci U S A. 2019;116(48):24231\u201341.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"1957_CR11","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/j.celrep.2019.10.038","volume":"29","author":"KA Waugh","year":"2019","unstructured":"Waugh KA, Araya P, Pandey A, Jordan KR, Smith KP, Granrath RE, et al. Mass cytometry reveals global immune remodeling with Multi-lineage hypersensitivity to type I interferon in down syndrome. Cell Rep. 2019;29(7):1893\u2013908. e4.","journal-title":"Cell Rep"},{"issue":"1","key":"1957_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12739-9","volume":"10","author":"RK Powers","year":"2019","unstructured":"Powers RK, Culp-Hill R, Ludwig MP, Smith KP, Waugh KA, Minter R, et al. Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors. Nat Commun. 2019;10(1):4766.","journal-title":"Nat Commun"},{"issue":"6","key":"1957_CR13","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s41588-023-01399-7","volume":"55","author":"KA Waugh","year":"2023","unstructured":"Waugh KA, Minter R, Baxter J, Chi C, Galbraith MD, Tuttle KD, et al. Triplication of the interferon receptor locus contributes to hallmarks of down syndrome in a mouse model. Nat Genet. 2023;55(6):1034\u201347.","journal-title":"Nat Genet"},{"key":"1957_CR14","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.2147\/JIR.S280953","volume":"14","author":"H Chung","year":"2021","unstructured":"Chung H, Green PHR, Wang TC, Kong XF. Interferon-Driven immune dysregulation in down syndrome: A review of the evidence. J Inflamm Res. 2021;14:5187\u2013200.","journal-title":"J Inflamm Res"},{"issue":"26","key":"1957_CR15","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg6218","volume":"9","author":"MD Galbraith","year":"2023","unstructured":"Galbraith MD, Rachubinski AL, Smith KP, Araya P, Waugh KA, Enriquez-Estrada B, et al. Multidimensional definition of the interferonopathy of Down syndrome and its response to JAK inhibition. Sci Adv. 2023;9(26):eadg6218.","journal-title":"Sci Adv"},{"issue":"9","key":"1957_CR16","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.1093\/rheumatology\/keab203","volume":"60","author":"AT Pham","year":"2021","unstructured":"Pham AT, Rachubinski AL, Enriquez-Estrada B, Worek K, Griffith M, Espinosa JM. JAK Inhibition for treatment of psoriatic arthritis in down syndrome. Rheumatology (Oxford). 2021;60(9):e309\u201311.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"1957_CR17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jdcr.2019.02.007","volume":"5","author":"AL Rachubinski","year":"2019","unstructured":"Rachubinski AL, Estrada BE, Norris D, Dunnick CA, Boldrick JC, Espinosa JM. Janus kinase inhibition in down syndrome: 2 cases of therapeutic benefit for alopecia areata. JAAD Case Rep. 2019;5(4):365\u20137.","journal-title":"JAAD Case Rep"},{"key":"1957_CR18","volume":"2022","author":"JT Jones","year":"2022","unstructured":"Jones JT. Treatment of down syndrome-associated arthritis with JAK inhibition. Case Rep Rheumatol. 2022;2022:4889102.","journal-title":"Case Rep Rheumatol"},{"key":"1957_CR19","doi-asserted-by":"crossref","unstructured":"Rachubinski AL, Wallace E, Gurnee E, Estrada BAE, Worek KR, Smith KP et al. JAK inhibition decreases the autoimmune burden in Down syndrome. medRxiv. 2024.","DOI":"10.7554\/eLife.99323.1"},{"key":"1957_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2024.578442","volume":"395","author":"AL Rachubinski","year":"2024","unstructured":"Rachubinski AL, Patel LR, Sannar EM, Kammeyer RM, Sanders J, Enriquez-Estrada BA, et al. Jak inhibition in down syndrome regression disorder. J Neuroimmunol. 2024;395:578442.","journal-title":"J Neuroimmunol"},{"issue":"25","key":"1957_CR21","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1182\/blood-2015-11-679902","volume":"127","author":"J Toubiana","year":"2016","unstructured":"Toubiana J, Okada S, Hiller J, Oleastro M, Lagos Gomez M, Aldave Becerra JC, et al. Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. Blood. 2016;127(25):3154\u201364.","journal-title":"Blood"},{"issue":"8","key":"1957_CR22","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1084\/jem.20110958","volume":"208","author":"L Liu","year":"2011","unstructured":"Liu L, Okada S, Kong XF, Kreins AY, Cypowyj S, Abhyankar A, et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med. 2011;208(8):1635\u201348.","journal-title":"J Exp Med"},{"issue":"7","key":"1957_CR23","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s10875-018-0557-0","volume":"38","author":"AR Bernasconi","year":"2018","unstructured":"Bernasconi AR, Yancoski J, Villa M, Oleastro MM, Galicchio M, Rossi JG. Increased STAT1 amounts correlate with the phospho-STAT1 level in STAT1 gain-of-function defects. J Clin Immunol. 2018;38(7):745\u20137.","journal-title":"J Clin Immunol"},{"key":"1957_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01433","volume":"10","author":"O Zimmerman","year":"2019","unstructured":"Zimmerman O, Olbrich P, Freeman AF, Rosen LB, Uzel G, Zerbe CS, et al. STAT1 gain-of-function mutations cause high total STAT1 levels with normal dephosphorylation. Front Immunol. 2019;10:1433.","journal-title":"Front Immunol"},{"issue":"2","key":"1957_CR25","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.jaci.2014.12.1867","volume":"135","author":"E Higgins","year":"2015","unstructured":"Higgins E, Al Shehri T, McAleer MA, Conlon N, Feighery C, Lilic D, et al. Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation. J Allergy Clin Immunol. 2015;135(2):551\u20133.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"1957_CR26","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s10875-022-01257-x","volume":"42","author":"A Deya-Martinez","year":"2022","unstructured":"Deya-Martinez A, Riviere JG, Roxo-Junior P, Ramakers J, Bloomfield M, Guisado Hernandez P, et al. Impact of JAK inhibitors in pediatric patients with STAT1 gain of function (GOF) mutations-10 children and review of the literature. J Clin Immunol. 2022;42(5):1071\u201382.","journal-title":"J Clin Immunol"},{"issue":"5","key":"1957_CR27","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1007\/s10875-023-01454-2","volume":"43","author":"P Olbrich","year":"2023","unstructured":"Olbrich P, Cortes JI, Neth O, Blanco-Lobo P, Iei D. Rheumatology research g. STAT1 Gain-of-Function and hidradenitis suppurativa successfully managed with baricitinib. J Clin Immunol. 2023;43(5):898\u2013901.","journal-title":"J Clin Immunol"},{"key":"1957_CR28","doi-asserted-by":"publisher","unstructured":"Fischer M, Olbrich P, Hadjadj J, Aumann V, Bakhtiar S, Barlogis V et al. JAK-inhibitor treatment for inborn errors of JAK\/STAT signaling: an ESID and EBMT IEWP retrospective study. J Allergy Clin Immunol. 2023;153(1):275\u2013286.e18. https:\/\/doi.org\/10.1016\/j.jaci.2023.10.018","DOI":"10.1016\/j.jaci.2023.10.018"},{"issue":"6","key":"1957_CR29","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s10875-022-01273-x","volume":"42","author":"PB Lobo","year":"2022","unstructured":"Lobo PB, Guisado-Hernandez P, Villaoslada I, de Felipe B, Carreras C, Rodriguez H, et al. Ex vivo effect of JAK inhibition on JAK-STAT1 pathway hyperactivation in patients with dominant-negative STAT3 mutations. J Clin Immunol. 2022;42(6):1193\u2013204.","journal-title":"J Clin Immunol"},{"issue":"4","key":"1957_CR30","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1089\/jir.2017.0127","volume":"38","author":"H Kim","year":"2018","unstructured":"Kim H, de Jesus AA, Brooks SR, Liu Y, Huang Y, VanTries R, et al. Development of a validated interferon score using nanostring technology. J Interferon Cytokine Res. 2018;38(4):171\u201385.","journal-title":"J Interferon Cytokine Res"},{"issue":"3","key":"1957_CR31","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1007\/s10875-021-01177-2","volume":"42","author":"MG Seidel","year":"2022","unstructured":"Seidel MG, Tesch VK, Yang L, Hauck F, Horn AL, Smolle MA, et al. The immune deficiency and dysregulation activity (IDDA2.1 \u2018Kaleidoscope\u2019) score and other clinical measures in inborn errors of immunity. J Clin Immunol. 2022;42(3):484\u201398.","journal-title":"J Clin Immunol"},{"issue":"2","key":"1957_CR32","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/cei\/uxad008","volume":"212","author":"AS Albuquerque","year":"2023","unstructured":"Albuquerque AS, Maimaris J, McKenna AJ, Lambourne J, Moreira F, Workman S, et al. Practical challenges for functional validation of STAT1 gain of function genetic variants. Clin Exp Immunol. 2023;212(2):166\u20139.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"1957_CR33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","volume":"166","author":"Laboratories ATSCoPSfCPF","year":"2002","unstructured":"Laboratories ATSCoPSfCPF. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111\u20137.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1957_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1365-2249.2011.04335.x","volume":"164","author":"G Ram","year":"2011","unstructured":"Ram G, Chinen J. Infections and immunodeficiency in Down syndrome. Clin Exp Immunol. 2011;164(1):9\u201316.","journal-title":"Clin Exp Immunol"},{"key":"1957_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.00073","volume":"8","author":"D Huggard","year":"2020","unstructured":"Huggard D, Doherty DG, Molloy EJ. Immune dysregulation in children with Down syndrome. Front Pediatr. 2020;8:73.","journal-title":"Front Pediatr"},{"issue":"5","key":"1957_CR36","doi-asserted-by":"publisher","first-page":"L892","DOI":"10.1152\/ajplung.00434.2020","volume":"321","author":"S Danopoulos","year":"2021","unstructured":"Danopoulos S, Deutsch GH, Dumortier C, Mariani TJ, Al Alam D. Lung disease manifestations in down syndrome. Am J Physiol Lung Cell Mol Physiol. 2021;321(5):L892-9.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"3","key":"1957_CR37","doi-asserted-by":"publisher","first-page":"E147","DOI":"10.1111\/j.1440-1754.2011.02077.x","volume":"48","author":"C Pandit","year":"2012","unstructured":"Pandit C, Fitzgerald DA. Respiratory problems in children with Down syndrome. J Paediatr Child Health. 2012;48(3):E147-52.","journal-title":"J Paediatr Child Health"},{"issue":"1","key":"1957_CR38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40119-021-00251-5","volume":"11","author":"DS Bush","year":"2022","unstructured":"Bush DS, Ivy DD. Pulmonary hypertension in the population with Down syndrome. Cardiol Ther. 2022;11(1):33\u201347.","journal-title":"Cardiol Ther"},{"issue":"6","key":"1957_CR39","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/j.jaci.2013.01.052","volume":"131","author":"EP Sampaio","year":"2013","unstructured":"Sampaio EP, Hsu AP, Pechacek J, Bax HI, Dias DL, Paulson ML, et al. Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis. J Allergy Clin Immunol. 2013;131(6):1624\u201334.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"1957_CR40","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/j.jaci.2012.11.054","volume":"131","author":"G Uzel","year":"2013","unstructured":"Uzel G, Sampaio EP, Lawrence MG, Hsu AP, Hackett M, Dorsey MJ, et al. Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathy-enteropathy-X-linked-like syndrome. J Allergy Clin Immunol. 2013;131(6):1611\u201323.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1957_CR41","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1189\/jlb.0513250","volume":"95","author":"Y Mizoguchi","year":"2014","unstructured":"Mizoguchi Y, Tsumura M, Okada S, Hirata O, Minegishi S, Imai K, et al. Simple diagnosis of STAT1 gain-of-function alleles in patients with chronic mucocutaneous candidiasis. J Leukoc Biol. 2014;95(4):667\u201376.","journal-title":"J Leukoc Biol"},{"issue":"4","key":"1957_CR42","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s40262-023-01225-7","volume":"62","author":"TYJ Appeldoorn","year":"2023","unstructured":"Appeldoorn TYJ, Munnink THO, Morsink LM, Hooge MNL, Touw DJ. Pharmacokinetics and pharmacodynamics of ruxolitinib: a review. Clin Pharmacokinet. 2023;62(4):559\u201371.","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"1957_CR43","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1016\/j.immuni.2022.09.007","volume":"55","author":"L Malle","year":"2022","unstructured":"Malle L, Martin-Fernandez M, Buta S, Richardson A, Bush D, Bogunovic D. Excessive negative regulation of type I interferon disrupts viral control in individuals with down syndrome. Immunity. 2022;55(11):2074\u2013e845.","journal-title":"Immunity"},{"issue":"5","key":"1957_CR44","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/eji.201847955","volume":"49","author":"E Kaleviste","year":"2019","unstructured":"Kaleviste E, Saare M, Leahy TR, Bondet V, Duffy D, Mogensen TH, et al. Interferon signature in patients with STAT1 gain-of-function mutation is epigenetically determined. Eur J Immunol. 2019;49(5):790\u2013800.","journal-title":"Eur J Immunol"},{"issue":"6","key":"1957_CR45","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1136\/ard-2022-223628","volume":"82","author":"J Rodriguez-Carrio","year":"2023","unstructured":"Rodriguez-Carrio J, Burska A, Conaghan PG, Dik WA, Biesen R, Eloranta ML, et al. 2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice. Ann Rheum Dis. 2023;82(6):754\u201362.","journal-title":"Ann Rheum Dis"},{"issue":"7951","key":"1957_CR46","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s41586-023-05736-y","volume":"615","author":"L Malle","year":"2023","unstructured":"Malle L, Patel RS, Martin-Fernandez M, Stewart OJ, Philippot Q, Buta S, et al. Autoimmunity in down\u2019s syndrome via cytokines, CD4 T cells and CD11c(+) B cells. Nature. 2023;615(7951):305\u201314.","journal-title":"Nature"},{"key":"1957_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.983977","volume":"13","author":"M Bloomfield","year":"2022","unstructured":"Bloomfield M, Zentsova I, Milota T, Sediva A, Parackova Z. Immunoprofiling of monocytes in STAT1 gain-of-function chronic mucocutaneous candidiasis. Front Immunol. 2022;13:983977.","journal-title":"Front Immunol"},{"issue":"6","key":"1957_CR48","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.4049\/jimmunol.160.6.2742","volume":"160","author":"D Guo","year":"1998","unstructured":"Guo D, Dunbar JD, Yang CH, Pfeffer LM, Donner DB. Induction of Jak\/STAT signaling by activation of the type 1 TNF receptor. J Immunol. 1998;160(6):2742\u201350.","journal-title":"J Immunol"},{"issue":"13","key":"1957_CR49","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.1128\/MCB.20.13.4505-4512.2000","volume":"20","author":"Y Wang","year":"2000","unstructured":"Wang Y, Wu TR, Cai S, Welte T, Chin YE. Stat1 as a component of tumor necrosis factor alpha receptor 1-TRADD signaling complex to inhibit NF-kappaB activation. Mol Cell Biol. 2000;20(13):4505\u201312.","journal-title":"Mol Cell Biol"},{"key":"1957_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.935394","volume":"13","author":"K Lambert","year":"2022","unstructured":"Lambert K, Diggins KE, Jones BE, Hundhausen C, Maerz MD, Hocking AM, et al. IL-6-driven pSTAT1 response is linked to T cell features implicated in early immune dysregulation. Front Immunol. 2022;13:935394.","journal-title":"Front Immunol"},{"key":"1957_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12950-019-0206-2","volume":"16","author":"S Perez-Baos","year":"2019","unstructured":"Perez-Baos S, Gratal P, Barrasa JI, Lamuedra A, Sanchez-Pernaute O, Herrero-Beaumont G, et al. Inhibition of pSTAT1 by tofacitinib accounts for the early improvement of experimental chronic synovitis. J Inflamm. 2019;16:2.","journal-title":"J Inflamm"},{"issue":"23","key":"1957_CR52","doi-asserted-by":"publisher","first-page":"6130","DOI":"10.12998\/wjcc.v8.i23.6130","volume":"8","author":"N Liu","year":"2020","unstructured":"Liu N, Zhao FY, Xu XJ. Hemophagocytic lymphohistiocytosis caused by STAT1 gain-of-function mutation is not driven by interferon-gamma: a case report. World J Clin Cases. 2020;8(23):6130\u20135.","journal-title":"World J Clin Cases"},{"issue":"5","key":"1957_CR53","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s00281-020-00804-1","volume":"42","author":"N Gensous","year":"2020","unstructured":"Gensous N, Bacalini MG, Franceschi C, Garagnani P. Down syndrome, accelerated aging and immunosenescence. Semin Immunopathol. 2020;42(5):635\u201345.","journal-title":"Semin Immunopathol"},{"issue":"1","key":"1957_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01486-5","volume":"8","author":"W Zhang","year":"2023","unstructured":"Zhang W, Xiao D, Mao Q, Xia H. Role of neuroinflammation in neurodegeneration development. Signal Transduct Target Ther. 2023;8(1):267.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"1957_CR55","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.12910","volume":"5","author":"MF Iulita","year":"2022","unstructured":"Iulita MF, Garzon Chavez D, Klitgaard Christensen M, Valle Tamayo N, Plana-Ripoll O, Rasmussen SA, et al. Association of Alzheimer disease with life expectancy in people with Down syndrome. JAMA Netw Open. 2022;5(5):e2212910.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"1957_CR56","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-024-01684-y","volume":"44","author":"L Dotta","year":"2024","unstructured":"Dotta L, Todaro F, Baronio M, Giacomelli M, Pinelli M, Giambarda M, et al. Patients with STAT1 gain-of-function mutations display increased apoptosis which is reversed by the JAK inhibitor ruxolitinib. J Clin Immunol. 2024;44(4):85.","journal-title":"J Clin Immunol"},{"issue":"4","key":"1957_CR57","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx202","volume":"4","author":"O Zimmerman","year":"2017","unstructured":"Zimmerman O, Rosler B, Zerbe CS, Rosen LB, Hsu AP, Uzel G, et al. Risks of ruxolitinib in STAT1 gain-of-function-associated severe fungal disease. Open Forum Infect Dis. 2017;4(4):ofx202.","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"1957_CR58","doi-asserted-by":"publisher","first-page":"e1204","DOI":"10.1542\/peds.2015-1652","volume":"136","author":"BS Zemel","year":"2015","unstructured":"Zemel BS, Pipan M, Stallings VA, Hall W, Schadt K, Freedman DS, et al. Growth charts for children with down syndrome in the united States. Pediatrics. 2015;136(5):e1204\u201311.","journal-title":"Pediatrics"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-025-01957-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-025-01957-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-025-01957-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T17:02:26Z","timestamp":1777309346000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-025-01957-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1957"],"URL":"https:\/\/doi.org\/10.1007\/s10875-025-01957-0","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"3 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"167"}}